Durable response with lenvatinib and pembrolizumab combination therapy in a patient with pre-treated metastatic cholangiocarcinoma

Authors

• Lena Dreikhausen Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
• Alexander Kusnik Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim; Preventive Medicine Baden-Württemberg (CPMBW), Medical Faculty Mannheim, Heidelberg University, Germany
• Nadine Schulte Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
• Maximilian Eckardt Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
• Andreas Teufel Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim; Preventive Medicine Baden-Württemberg (CPMBW), Medical Faculty Mannheim, Heidelberg University, Germany
• Timo Gaiser Institute of Pathology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
• Matthias Ebert Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim; Preventive Medicine Baden-Württemberg (CPMBW), Medical Faculty Mannheim, Heidelberg University, Germany
• Tianzuo Zhan Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany